In accordance with scRNA-seq data, the Oxali + anti–PD-L1 combo increased the percentage and/or total numbers of tumor-infiltrating CD8+ and CD4+ T cells, CD107+IFNγ+ CTLs, IFNγ+ CD8+, and TNF+IFNγ+ CD8+ T cells, CD8+CD44+ Teff cells, and CD8+CD44+PD1+TIM-3+ T cells analyzed by flow cytometry (Fig. 7 M and N and SI Appendix, Fig. S16 A and C–H). The gene discussed is CD44; the disease is neoplasm.